Mark Peterson

uniQure’s promising gene therapy for Huntington's disease hits a major FDA roadblock, sending its stock tumbling and delaying hope for patients.

How a craft soda maker and a gaming giant turned a niche beverage into a national sensation, rewriting the rules of fan engagement and retail strategy.

A $1.8M military deal for its unique aluminum foam positions Cymat to capitalize on rising defense spending. But can it turn tech wins into profit?

The European Commission dismissed NGO objections to a key copper project, signaling a new era for Europe's resource security and its green transition.

With a micro-financing, new board, and a 15-for-1 share consolidation, is junior explorer Infinico Metals executing a savvy turnaround or just surviving?

The Danish biotech just locked in billions in financing for its Merus N.V. buyout. It's a high-stakes bet on a new cancer drug to redefine its future.

A biotech firm's novel 'CD45 engager' could make off-the-shelf cell therapies a reality, starting with a tough-to-treat blood cancer. Is this a market disruptor?

A 30% dealer sales jump shows demand for American-made safes. But can this success secure the future of its financially struggling parent company, AREB?

RNAi leader Alnylam swaps scientific oversight for commercial firepower in a key board reshuffle, signaling a strategic pivot to dominate the market.

After a $1B trial in Brazil, Rezolve AI is bringing its AI-powered stablecoin payment system to the West. Can it navigate the regulatory maze?

Beyond the numbers, CACI's renewed $145M pact with the U.S. Navy is a critical investment in America's submarine readiness. Here's the strategic analysis.

Stem's move to add CEO Arun Narayanan to its board is more than a title change; it's a strategic gambit to accelerate its software-first future.

Unilever is shedding its €7.9B ice cream division. We dive into the strategy behind the split and what Magnum's debut means for investors and rivals.

A simple meeting delay hides a high-stakes battle. Lee Enterprises is fighting activist investors and crushing debt. This vote could decide its future.

A pivotal $30M contract catapults Sunrise New Energy into high-growth energy storage and UAV markets, but can it challenge the industry giants?

A small cybersecurity firm just gained access to Florida's $90M consulting budget. Is this a game-changing opportunity or a high-stakes bet for Cycurion?

Zevra Therapeutics adds M&A expert Alicia Secor to its board, a move signaling a sharpened focus on commercial growth and strategic transactions.

CTW Cayman is bypassing app stores with HTML5 games. Its new Crayon Shinchan title reveals a disruptive strategy leveraging anime IP for global dominance.

A tiny mouse's song reveals a new path for evolution and technology. CSHL's research could disrupt everything from AI to treatments for speech disorders.

With EU approval for its novel acne drug Winlevi, Glenmark makes a strategic pivot, challenging dermatology incumbents and testing its European ambitions.